QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region

• New facility reflects QIAGEN’s commitment to enhancing its bioinformatics data center infrastructure in the Australia, New Zealand, New Guinea and surrounding islands region

• New data center in Melbourne meets Australian regulations to ensure quality, scalable and trustworthy support for Omics analysis and interpretation in genomic testing labs

• Expands a QIAGEN network of seven data centers around the globe designed to ensure highest level of data security, compliance and operational excellence worldwide

VENLO, The Netherlands & REDWOOD CITY, Calif.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the official opening of a new data center in Melbourne, Australia, designed to strengthen its global bioinformatics leadership position in this region of the world.

This latest addition reflects QIAGEN’s ongoing commitment to enhance its bioinformatics data infrastructure, enabling initiatives to broaden the reach and use of bioinformatics products in the Australia/Asia-Pacific region – which encompasses Australia, New Zealand, New Guinea and surrounding islands.

It will also expand the current QIAGEN network of seven data centers strategically located across the United States, United Kingdom, Denmark, Turkey, South Korea, Japan and China.

This investment supports the expanding data center market in the Australia/Asia-Pacific region while ensuring local compliance and high-quality solutions for Omics analysis and interpretation in genomic testing laboratories.

The new Melbourne facility will provide in-country data hosting, supporting genomic testing labs in Australia to securely host sensitive data while complying with Australian privacy and health data regulations. It underscores QIAGEN’s commitment to providing tailored bioinformatics solutions that enable secure, efficient and innovative clinical and diagnostic services.

”With the opening of this data center, we are strengthening our ability to serve the Australian market and the broader Australia/Asia-Pacific region,” said Dominic John, Vice President, QIAGEN Digital Insights. ”This new facility will allow diagnostic labs to confidently deliver clinical next-generation sequencing testing services while meeting evolving data sovereignty laws. Now operating eight data centers around the globe, we are ensuring data security, compliance and operational excellence worldwide.”

As the use of clinical next-generating sequencing (NGS) continues to evolve, QIAGEN remains at the forefront, delivering innovative bioinformatics solutions that empower labs and researchers to unlock the full potential of genomics and personalized medicine.

With over 25 years of experience in the industry, 90,000 users worldwide, and 4 million profiled patient cases, QDI is committed to accelerating breakthroughs in science and healthcare by providing intuitive, scalable solutions that transform complex biological information into clear, actionable insights.

For more information about QIAGEN Digital Insights and its global data infrastructure, visit https://digitalinsights.qiagen.com/.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. For more information, visit www.qiagen.com.

Forward-Looking Statement

Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results and allocations between customer classes, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the “Risk Factors” contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.

Source: QIAGEN N.V.

Category: Corporate
Contacts

Contacts QIAGEN:
Investor Relations
John Gilardi +49 2103 29 11711
Domenica Martorana +49 2103 29 11244
e-mail: [email protected]

Public Relations
Thomas Theuringer +49 2103 29 11826
Lisa Specht +49 2103 29 14181
e-mail: [email protected]